Mitotane

SKU: orb1309439

Description

Mitotane is an adrenocorticolytic agent derived from DDD, selectively targeting and inhibiting adrenal cortical cells and hormone production. It is used in research models of adrenocortical carcinoma and Cushing's syndrome, with studies demonstrating its cytotoxic effects in both in vitro and in vivo experimental settings.

Research Area

Cell Biology, Neuroscience

Key Properties

• CAS Number: 53-19-0
• MW: 320.04
• Purity: 99.96% (May vary between batches)
• Formula: C₁₄H₁₀Cl₄
• SMILES: ClC(Cl)C(c1ccc(Cl)cc1)c1ccccc1Cl
• Target: Apoptosis,AChR
• Solubility: H2O:< 1 mg/mL (insoluble or slightly soluble);DMSO:60 mg/mL (187.48 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (6.25 mM);Ethanol:60 mg/mL (187.48 mM)

Bioactivity

• In Vivo:
  10-40 μM Mitotane inhibited basal and cAMP-induced cortisol secretion but did not cause cell death.Mitotane inhibited basal expression of StAR and P450scc proteins.40 μM Mitotane significantly reduced mRNA expression of StAR, CYP11A1 and CYP21.In H295R cells, the mRNA expression of StAR, CYP11A1 and CYP21 was significantly reduced by Mitotane. In H295R cells, Mitotane in combination with gemcitabine showed antagonistic effects and interfered with gemcitabine-mediated S-phase inhibition of the cell cycle.Mitotane inhibited the expression and secretion of thyroid stimulating hormone (TSH), blocked TSH response to thyrotropin-releasing hormone (THRH), decreased cell viability, and induced apoptosis in the mouse TalphaT1 cell line.Mitotane inhibited the expression and secretion of pituitary thyrotropin secretory hormone (PTHS) and induced apoptosis in the pituitary thyrotropin secretory hormone (PSH) cells. Mitotane induced adrenocortical necrosis, mitochondrial membrane damage, and irreversible binding of the protein CYP in pituitary thyrotropin-secreting mouse cells, without interfering with thyroid hormones, and directly reduced secretory activity and cell viability.
• In Vitro:
  10-40 μM Mitotane inhibited basal and cAMP-induced cortisol secretion but did not cause cell death.Mitotane inhibited basal expression of StAR and P450scc proteins.40 μM Mitotane significantly reduced mRNA expression of StAR, CYP11A1 and CYP21.In H295R cells, the mRNA expression of StAR, CYP11A1 and CYP21 was significantly reduced by Mitotane. In H295R cells, Mitotane in combination with gemcitabine showed antagonistic effects and interfered with gemcitabine-mediated S-phase inhibition of the cell cycle.Mitotane inhibited the expression and secretion of thyroid stimulating hormone (TSH), blocked TSH response to thyrotropin-releasing hormone (THRH), decreased cell viability, and induced apoptosis in the mouse TalphaT1 cell line.Mitotane inhibited the expression and secretion of pituitary thyrotropin secretory hormone (PTHS) and induced apoptosis in the pituitary thyrotropin secretory hormone (PSH) cells. Mitotane induced adrenocortical necrosis, mitochondrial membrane damage, and irreversible binding of the protein CYP in pituitary thyrotropin-secreting mouse cells, without interfering with thyroid hormones, and directly reduced secretory activity and cell viability.

Storage & Handling

• Storage: store under nitrogen | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Mitotan, Mitotane, o,p'-DDD, NCI-C04933, NCI-C-04933, NCI-C 04933, Inhibitor, inhibit, H295R, HepaRG, cholesterol, drug-drug interactions, corticotroph cells, antineoplastic, Apoptosis, 2,4′-DDD, adrenocortical carcinoma, Adrenodoxin, TαT1

Compound Identifiers

PubChem CID

4211